Intrathecal Amphotericin B: A 60-Year Experience in Treating Coccidioidal Meningitis

Clin Infect Dis. 2017 Feb 15;64(4):519-524. doi: 10.1093/cid/ciw794.

Abstract

Coccidioidal meningitis (CM) is a devastating complication of coccidioidomycosis. Since the late 1950s, intrathecal (IT) amphotericin B deoxycholate (AmBd) has been successfully used to treat and often cure this disease, reducing mortality rates from 100% to approximately 30%. The introduction of azoles further revolutionized the treatment of coccidioidal infections. However, IT AmBd remains the only known curative option in the management of CM. While the use of IT AmBd is well described in many articles, few discuss the actual methods behind preparation, titration, and dosing strategies utilized. The practitioners at Kern Medical (Bakersfield, California) have >60 years of experience in the utilization of IT AmBd and the treatment of CM. This article describes the practice experience in the treatment of CM, preparation of IT AmBd, and the different dosing strategies used in regard to route of administration (ie, cisternal, lumbar, ventricular).

Keywords: Coccidioidal meningitis; amphotericin; azole therapy; fungal infection; intrathecal therapy.

Publication types

  • Review

MeSH terms

  • Amphotericin B / administration & dosage*
  • Antifungal Agents / administration & dosage*
  • Coccidioidomycosis / drug therapy*
  • Humans
  • Injections, Spinal / methods*
  • Meningitis / drug therapy*

Substances

  • Antifungal Agents
  • Amphotericin B